BEIJING TONGRENTANG CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.77 CNY | -0.24% |
|
+1.19% | -22.22% |
| Mar. 28 | Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 06 | China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug | MT |
| Sales 2024 * | 20.24B 2.8B | Sales 2025 * | 22.69B 3.14B | Capitalization | 57.29B 7.91B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.94B 268M | Net income 2025 * | 2.26B 312M | EV / Sales 2024 * | 2.23 x |
| Net cash position 2024 * | 12.22B 1.69B | Net cash position 2025 * | 13.81B 1.91B | EV / Sales 2025 * | 1.92 x |
| P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
25.6
x | Employees | 16,777 |
| Yield 2024 * |
1.36% | Yield 2025 * |
1.4% | Free-Float | 47.55% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.24% | ||
| 1 week | +1.19% | ||
| Current month | +1.90% | ||
| 1 month | -3.18% | ||
| 3 months | -17.68% | ||
| 6 months | -15.79% | ||
| Current year | -22.22% |
1 week
40.30
42.51
1 month
40.3043.34
Current year
39.7155.74
1 year
39.7164.28
3 years
28.2464.28
5 years
23.2564.28
10 years
16.3564.28
| Managers | Title | Age | Since |
|---|---|---|---|
Chao Hua Zhang
CEO | Chief Executive Officer | 50 | 21-06-24 |
Li Yang
BRD | Director/Board Member | 46 | 21-06-24 |
Kai Ting Wen
BRD | Director/Board Member | 46 | 20-04-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qing Ying Yang
BRD | Director/Board Member | 70 | 23-01-08 |
Yi Zang
BRD | Director/Board Member | 47 | 18-06-12 |
Bai Gang Liu
BRD | Director/Board Member | 56 | 18-06-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.17% | 2 M€ | -14.14% | ||
| 1.07% | 2 M€ | -19.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 41.77 | -0.24% | 11,462,780 |
| 24-04-17 | 41.87 | +2.22% | 13,478,390 |
| 24-04-16 | 40.96 | -0.56% | 9,984,475 |
| 24-04-15 | 41.19 | +0.41% | 10,221,730 |
| 24-04-12 | 41.02 | -0.63% | 6,590,402 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Companyâs main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
41.77
CNY
Average target price
53.25
CNY
Spread / Average Target
+27.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.22% | 7.93B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 600085 Stock
